Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin glargine injection vs Lantus in type 2 diabetes
CTR20161012Phase 3Completed
- Sponsor
- YiChang HEC ChangJiang Pharmaceutical
- Start
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by YiChang HEC ChangJiang Pharmaceutical. Started Jan 2017; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20161012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20161012.